M. William Audeh

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Gynecology, Oncology +16

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation

Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler et al. · Journal of Clinical Oncology · 2014 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · The Lancet · 2010 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +13

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Susan M. Domchek, Carol Aghajanian, Ronnie Shapira‐Frommer et al. · Gynecologic Oncology · 2015 · 300 citations · Full text

Medicine, Gynecology, Oncology +17

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · Journal of Clinical Oncology · 2009 · 175 citations

Medicine, Oncology, Pharmacology +15